Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at $240.00.
Larry Biegelsen has given his Buy rating due to a combination of factors that underscore the strength and potential of Insulet’s financial position and market performance. Notably, Insulet produces the Omnipod, a successful insulin pump, which maintains a significant presence in the market. Despite the recent court developments allowing EOFlow to continue developing and commercializing its competing patch pump, Biegelsen likely sees Insulet’s market position and product success as indicators of continued growth and resilience. Additionally, the financial metrics, such as a remarkable return on invested capital (ROIC) and a positive three-year earnings per share (EPS) compound annual growth rate (CAGR), suggest a robust financial outlook for Insulet.
Biegelsen’s analysis may also consider the broader context of Insulet’s legal battles and competitive landscape. While the preliminary injunction against EOFlow was lifted, the underlying strength of Insulet’s product offering and intellectual property portfolio could provide confidence in its ability to navigate these challenges. Furthermore, the market expansion of Insulet’s Omnipod, along with the company’s strong financial indicators, such as substantial daily trading volume and manageable net debt, could reinforce the Buy rating as a reflection of the company’s capacity for long-term value creation despite near-term legal uncertainties.
In another report released on May 10, Piper Sandler also maintained a Buy rating on the stock with a $230.00 price target.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PODD in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Insulet (PODD) Company Description:
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Read More on PODD:
